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Postmenopausal 
estrogen use and 
Parkinson’s disease 
with and without 
dementia 
Article a b s t r a c b w e  investigated the effects of estrogen replacement ther- 
apy (ERT) on the risk of development of dementia in 87 women with Parkin- 
son’s disease without dementia (PDND), 80 women with Parkinson’s disease 
with dementia (PDD), and 989 nondemented healthy women from the same 
community. ERT was protective for the development of dementia within the 
setting of PD (OR 0.22, 95% CI 0.05-1.0) and when PDD patients were 
compared with controls (OR 0.24, 95% CI 0.07-0.78), but did not affect the 
risk of PD. The results of the study suggest that  a randomized clinical trial of 
ERT may be warranted. 
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Risk factors for Parkinson’s disease with dementia 
(PDD) include age a t  onset of the motor signs of PD, 
the presence of severe extrapyramidal signs, and de- 
pression.’ It is unknown to what extent PDD over- 
laps with Alzheimer’s disease (AD) or whether the 
risk factors for AD are also risk factors for PDD. 
ApoE4 has not been associated with PDD, and no 
other genetic susceptibility loci for PDD have been 
identified. 
Three prospective, observational studies demon- 
strated reduced risk and delayed age at onset of AD 
in postmenopausal women who used e ~ t r o g e n , ~ - ~  
whereas one did not.5 To determine whether estro- 
gen replacement therapy (ERT) reduced the risk of 
dementia in women with PD, estrogen usage was 
ascertained in 167 women with PD, 80 of whom were 
demented, as well as in 989 nondemented women 
from the same community. 
Methods. Patients were participants in a population- 
based community survey of PD in Washington Heights- 
Inwood, New York, NY.fi The diagnosis of PD was 
established according to published research criteria.‘j Pa- 
tients with secondary parkinsonism and multisystem atro- 
phy as well as those who experienced cognitive impairment 
before the development of the motor manifestations of PD 
were excluded. Healthy nondemented controls without PD 
were identified from a random sample of Medicare recipi- 
ents from the same geographic region as the patients. The 
participation rate averaged 68%. Both patients and con- 
trols underwent a structured neurologic examination and a 
neuropsychological battery. Dementia was defined based 
on the criteria established in the Diagnostic and Statistical 
Manual of Mental Disorders, Third Edition, Revised. 
Demographic information collected on patients and con- 
trols included age, education, and ethnicity classified by 
self-report as Caucasian, African-American, or Hispanic. 
Data on current and past ERT were combined because 
very few subjects were currently taking estrogen. Data on 
demented patients were obtained from informants. 
For a subset of patients and all controls, apoE geno- 
types were determined. ApoE4 was included in the analy- 
ses because of its potential interaction with estrogen, as 
well as the known association with AD. 
Demographic characteristics of pa- 
tients with and without dementia and controls were com- 
Data analysis. 
pared using Student’s t-test for continuous variables and 
chi-square tests for categorical variables. Three separate 
logistic regression models were constructed. First we esti- 
mated the odds ratio (OR) for the association of ERT and 
dementia in patients with PD by comparing patients with 
PDD with patients with PD without dementia (PDND). In 
the second model, to determine whether ERT was associ- 
ated with PDD, we compared PDD patients with controls. 
In the third model, to determine whether ERT was associ- 
ated with risk of PD, PDND patients were compared with 
controls. Crude and adjusted ORs were calculated for each 
model. Covariates in each model included age, education, 
and ethnicity. In a separate analysis, the presence of an 
ApoE4 allele was included as a covariate. 
Results. Summary statistics and univariate comparisons 
of the demographic characteristics of the 87 PDND pa- 
tients, 80 PDD patients, and 989 controls are presented in 
table 1. Crude and adjusted ORs are presented in table 2. 
The first logistic model examined the association be- 
tween ERT and dementia in the setting of PD (PDD com- 
pared with PDND), adjusting for age, education, and 
ethnic group. ERT was associated with a lower risk of 
dementia (adjusted OR 0.22, 95% CI 0.05-1.0, p < 0.05) in 
women with PD. 
The second logistic model examined the association between 
ERT and PDD patients by comparing this group with con- 
trols. Again, ERT was associated with a lower risk of PDD 
(adjusted OR 0.24, 95% CI 0.07-0.78, p < 0.01). The pres- 
ence of an apoE4 allele did not change the point estimate 
for ERT (adjusted OR 0.29, 95% CI 0.07-1.26, p < 0.09). 
The third logistic model examined the association be- 
tween estrogen and PD by including only PDND patients 
and controls. ERT was not associated with PD (adjusted 
OR 1.02, 95% CI 0.56-1.8,~ < 0.94). 
Discussion. ERT in postmenopausal women did 
not affect the risk of PD but may have been associ- 
ated with a lower risk of dementia in women with 
PD. To our knowledge, this is the first study to ex- 
amine the association between estrogen and demen- 
tia in the setting of PD. The prevalence of PDD in 
community-based series ranges from 20 to 40%. The 
presence of dementia often precludes the usage of 
high doses of medication to treat the movement dis- 
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Table 1 Demographics 
~~ 
Con t r o 1 s PDND PDD 
(n = 989) (n = 87) (n = 80) Significance 
Mean age in years (SD) 74.2 (6.5) 71.2 (9.9) 79.0 (7.0) p < 0.001 
Education in years (SD) 9.6 (4.5) 10.6 (4.9) 8.7 (3.9) p < 0.02 
Ethnicity 
Caucasian 285 (28.8%) 40 (46.0%) 36 (45.0%) p < 0.003 
African American 203 (20.5%) 15 (17.2%) 14 (17.5%) 
Hispanic 494 (49.9%) 21 (35.6%) 30 (37.5%) 
Other 7 (0.7%) l(l.l%) 
ERT 154 (15.6%) 15 (17.2%) 3 (3.8%) p < 0.001 
Family history of AD 211 (24.9%) 17 (23.3%) 12 (24%) ns 
n = 846 n = 73 n = 50 
At least one apoE4 allele 180 (27.6%) 15 (28.3%) 12 (33.5%) ns 
n = 651 n = 53 n = 36 
_ _ _ _ ~  ~~ 
PDND = Parkinson’s disease without dementia; PDD = Parkinson’s disease with dementia; ERT = estrogen replacement therapy; 
AD = Alzheimer’s disease; ns = not significant. 
order. In both clinic-based and community-based 
studies, dementia is associated with an increased 
risk of mortality in patients with PD. Treatment of 
dementia in PD has been ineffective. Therefore, de- 
laying the onset of dementia in PD would allow 
greater flexibility for treating the motor manifesta- 
tions of PD and might prolong survival. 
The dementia associated with PD has been as- 
cribed to degeneration of the medial aspect of the 
substantia nigra in patients without concomitant 
AD, to the presence of diffuse Lewy bodies, and to 
AD. In the recently published criteria for the diagno- 
sis of dementia with Lewy bodies (DLB), the pres- 
ence of the neuropathologic hallmarks of AD was not 
inconsistent with the diagnosis of DLB; AD neuropa- 
thology was noted to be present in most cases. In a 
subset of patients with PDD, coincident AD may be 
the sole etiology for the dementia. 
In cross-sectional studies and three prospective 
observational ~ t u d i e s , ~ - ~  ERT has been associated 
with a reduced relative risk of AD (0.3 to  0.4) and a 
dose-response effect with lower risk associated with 
greater use. Although some studies may be con- 
founded by socioeconomic factors and education that 
may have distinguished estrogen users from non- 
users, several lines of evidence support the hypo- 
thesis that estrogen may protect against the 
development of AD. First, in studies of healthy 
women participating in a double-blind, placebo- 
controlled trial of ERT tested before and after sur- 
gical menopause, ERT enhanced both short- and 
long-term verbal memory, but had no effect on visual 
mem01-y.~ Second, morphologic studies demonstrated 
that estrogen treatment increases the density of den- 
dritic spines in the CA1 region of rat hippocampus,8 
perhaps by activating N-methybaspartate recep- 
tors also present in the CA1 r e g i ~ n . ~  Finally, ERT in 
ovariectomized rats has been shown to induce the 
enzyme choline acetyltransferase, the rate limiting 
step for the formation of acetylcholine. This trophic 
effect may be mediated by nerve growth factor that 
has been shown to co-localize with estrogen receptors 
in cholinergic neurons of the basal forebrain of rats.lo 
Although the possible protective effect of ERT 
seen in the present study of women with PD is con- 
sistent with data collected in women with AD, there 
are several potential limitations. The data collection 
was retrospective. There is a possibility that there 
Table 2 Association of estrogen replacement therapy among patients with PDD and PDND, as well as controls 
Crude OR 95% CI Sig. Adjusted OR 95% CI Sig. 
Model 1 
PDD vs PDND 0.18 0.05-0.66 p < 0.01 0.22 0.05-1.0 p < 0.05 
Model 2 
p < 0.01 PDD vs controls 0.21 0.07-0.67 p < 0.01 0.24 0.07-0.78 
Model 3 
PDND vs controls 1.1 0.63-2.0 ns 1.02 0.56-1.8 ns 
PDD = Parkinson’s disease with dementia; PDND = Parkinson’s disease without dementia; OR = odds ratio; CI = confidence inter- 
vals; Sig. = significance; ns = not significant. 
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was underreporting of estrogen use in the PDD 
group because information on ERT was derived from 
the informants of PDD patients, whereas both con- 
trols and PDND patients provided their own risk- 
factor information. In addition, although age, 
ethnicity, and education were adjusted for in the 
analysis, these characteristics may have influenced 
the subjects’ opportunity to obtain ERT or the physi- 
cians’ decision to offer it. Although age was a covari- 
ate in the logistic regression models, the PDD group 
was significantly older than the PDND and control 
groups. Some of these limitations could be addressed 
by conducting a prospective study or a randomized 
double-blind clinical trial. 




Article abstract-We report a family with band heterotopia in a mother and 
daughter and lissencephaly in a son (X-linked inheritance pattern). Postmor- 
tem examination of the boy revealed classical lissencephaly and, among other 
findings, simplified and discontinuous inferior olives without inferior olivary 
heterotopia. The absence of inferior olivary heterotopia may distinguish 
~ ~~ ~ 
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In 1994, Pinard et al.’ described two families with 
mothers and daughters with band heterotopia and 
sons with classical lissencephaly (a total of six people 
affected). This syndrome was termed “X-linked liss- 
encephaly and subcortical band heterotopia” by 
Dobyns and Truwit.2 Classical lissencephaly occurs 
in several conditions, including isolated lissenceph- 
aly sequence and Miller-Dieker syndrome. In addi- 
tion to the cerebral abnormality, inferior olivary 
heterotopia are present in all but two reported pa- 
tients with classical lissencephaly.3-6 We report an 
additional family with band heterotopia in a mother 
and daughter and classical lissencephaly in a son 
without inferior olivary heterotopia. 
Case reports. Patient 1. This patient (the mother of 
Patients 2 and 3) is a 29-year-old woman who developed 
habitual partial and generalized seizures a t  the age of 13 
years. She has mild mental retardation with visual percep- 
tual and fine motor deficits on neuropsychological evalua- 
tion. MRI demonstrated bilaterally symmetric, moderately 
thick band heterotopia (figure 1). 
This patient (the daughter of Patient 1) is a 
4-year-old girl born at 42 weeks’ gestation with a birth 
Patient 2. 
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